What is imipenem and cilastatin injection used for?
Pharmaceutical Product Monograph: Imipenem and Cilastatin (250 mg, 500 mg)
In the pharmaceutical industry, Imipenem and Cilastatin is a parenteral, broad-spectrum Carbapenem antibiotic combination. As a pharmacist and manufacturer, I view this molecule as the “Empirical Powerhouse”—it is technically designed to provide one of the broadest spectrums of antibacterial activity available, covering nearly all clinically relevant Gram-positive, Gram-negative, and anaerobic pathogens.
At your WHO-GMP facility in Mumbai, Imipenem/Cilastatin is a high-value Critical Care and ICU SKU. It is typically reserved for life-threatening, multi-drug resistant (MDR) infections where other antibiotics have failed.
Therapeutic Profile: Primary Indications
This combination is indicated for severe, mixed, or “unknown” infections in hospitalized patients.
| Indication | Clinical Context | Technical Rationale |
| Intra-abdominal Infections | Peritonitis / Abscess | Gold Standard: Covers the complex mix of aerobic and anaerobic bacteria found in gut perforations. |
| Nosocomial Pneumonia | VAP / HAP | Targets resistant Klebsiella and Enterobacter species in ventilator-dependent patients. |
| Complicated UTI | Pyelonephritis | Highly effective against ESBL-producing E. coli that are resistant to cephalosporins. |
| Septicemia | Bloodstream Infection | Used as empirical “Best-Guess” therapy for patients in septic shock with an unknown source. |
| Gynecological Infections | Severe PID / Endometritis | Treats deep pelvic infections involving resistant anaerobic flora. |
Mechanism: The Dual-Action System
This product is a fixed-dose combination (1:1 ratio) because Imipenem cannot function effectively alone in the human body.
Imipenem (The Killer): It binds to Penicillin-Binding Proteins (PBPs), primarily PBP-2 and PBP-1B, in the bacterial cell wall. This inhibits the final cross-linking of peptidoglycan, leading to rapid bacterial Lysis (bursting). It is highly resistant to most beta-lactamase enzymes.
Cilastatin (The Protector): Imipenem is naturally broken down by an enzyme in the human kidney called Dehydropeptidase-I. Without Cilastatin, the drug would be neutralized before it could work. Cilastatin is a Dehydropeptidase inhibitor that prevents this breakdown, ensuring high levels of active Imipenem reach the urine and bloodstream.
Nephroprotection: Cilastatin also technically prevents the accumulation of Imipenem metabolites in the renal tubules, reducing the risk of kidney toxicity.
The Pharmacist’s “Technical Warning”
The “Seizure” Risk: As a pharmacist, I must emphasize that Imipenem is associated with Central Nervous System (CNS) side effects, including tremors and seizures. This risk is technically higher in patients with pre-existing CNS disorders or those with decreased kidney function who are given too high a dose.
Renal Adjustment: Dosage must be strictly adjusted based on the patient’s Creatinine Clearance. Accumulation of the drug leads directly to neurotoxicity.
The “Valproic Acid” Interaction: Imipenem can technically drop the blood levels of Valproic Acid (an anti-seizure med) by up to 60% to 100% within 24 hours. This combination should be avoided to prevent breakthrough seizures.
The “Ganciclovir” Warning: Concurrent use with the antiviral Ganciclovir increases the risk of generalized seizures and is technically contraindicated.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Lyophilized Stability” USP: Imipenem is chemically unstable in liquid form. On your digital marketplace, highlight your Aseptic Lyophilization (Freeze-Drying). This ensures the 500 mg/500 mg powder is stable for 24 months. Once reconstituted, it must be used within 4 hours at room temperature or 24 hours if refrigerated.
The “Carbapenem-Only” Facility: To meet international B2B standards, you must emphasize that these are produced in a dedicated, segregated facility to prevent cross-contamination with other antibiotics (like Penicillins or Cephalosporins), which is a critical regulatory requirement.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Imipenem and Cilastatin 500 mg/500 mg vials to support your registration in international B2B tenders for hospital and critical care.